logo
Safety Body Warns Over Post-Discharge Information Gaps

Safety Body Warns Over Post-Discharge Information Gaps

Medscapea day ago
Communication failures between hospitals and community services after patient discharge can lead to serious medication-related harm, a new report has warned.
The Health Services Safety Investigations Body (HSSIB) found that gaps in patient records, poor information sharing, and insufficient post-discharge support can delay or prevent medication being taken, with potentially life-threatening consequences.
Case Study: Missed Insulin After Discharge
The investigation examined the case of a 53-year-old man whose diabetes medication was changed during a hospital stay.
Although he received some education on self-administering insulin, he later said he struggled to remember the instructions. A referral for district nursing support was made via his GP, but the district nursing team was not informed.
Seventeen days after discharge, he told a nurse that he had not been taking insulin. His glucose levels were dangerously high, leading to an emergency hospital readmission.
Key Failings Identified
The HSSIB identified several failings:
Conflicting records on admission made it unclear whether the patient had been taking diabetes medication.
No documented evidence confirmed his ability to self-administer insulin after discharge education.
Communication about the need for district nursing support was inconsistent between hospital teams and community services, and no specific support for insulin administration was arranged.
The patient was discharged with two insulin pens, one of which was unnecessary, causing him confusion.
District nursing demand often exceeded capacity, limiting visit times.
Multiple providers used incompatible electronic patient record systems, preventing the sharing of critical information.
Recommendations for Safer Discharges
The report calls for local-level learning prompts covering hospital care, discharge planning, and community follow-up to prevent similar risks.
It stressed the importance of ensuring patients are confident in managing their medication before leaving hospital and improving interoperability between hospital and community electronic systems.
'A Matter of Patient Safety'
Rebecca Doyle, safety investigator at HSSIB, said that improving information flow and patient support at discharge is more than an administrative task.
'It's a matter of patient safety,' she said. 'While individual cases can be complex, this incident clearly highlighted persistent challenges with information sharing – an issue we continue to see in investigations that explore communication and the interaction of digital systems. This information sharing is critical to keep people safe at home, managing their medical conditions, and avoiding readmission to hospital.'
The report is the third and final in a series of HSSIB investigations exploring why medications intended to be given to patients were not given.
Priscilla Lynch is a freelance writer for Medscape, with over 20 years' experience covering medicine and healthcare. She has a master's in journalism and recently undertook a Health Innovation Journalism Fellowship with the International Center for Journalists.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Meat, dairy allergies from tick bites "skyrocketing" on Martha's Vineyard, expert says
Meat, dairy allergies from tick bites "skyrocketing" on Martha's Vineyard, expert says

CBS News

time28 minutes ago

  • CBS News

Meat, dairy allergies from tick bites "skyrocketing" on Martha's Vineyard, expert says

There's a new medical issue on Martha's Vineyard, and it's impacting the way people eat. It's known as "alpha-gal syndrome," and is not a tick-borne illness, but rather an allergy in response to a tick bite. "It's skyrocketing across the island," explained Patrick Roden-Reynolds, a biologist and tick researcher on Martha's Vineyard. The allergy can come in response to a bite from a Lone Star tick, which are common in the south but have recently shown up in large numbers on the Vineyard - due to a combination of climate and an unusually large deer population, experts say. "In the last 15 years, the Lone Star tick has gone from non-existent on the island to fully abundant and everywhere," Roden-Reynolds explained. "So, the way I've been explaining it, our public health burden with just deer ticks and Lyme disease was, you know, already here at our eyeballs, and now with the Lone Star tick and alpha-gal concerns, it's way above our head." The allergy can cause a range of symptoms up to serious anaphylaxis in response to eating or even being near mammal meat, dairy, and some mammal-related products inside medicine. "Alpha-gal syndrome has been so explosive on Martha's Vineyard that pretty much it comes up in every conversation that I have, ticks or alpha-gal syndrome, even without folks knowing what I do for work," explained Lea Hamner, an epidemiologist on the island. Hamner provided WBZ with a graph that shows the increase in positive allergy testing on the island - from 32 in 2021 to more than 500 positive tests in 2024. There is still a lot to learn about the allergy, Hamner says, though one thing is known: people can go into remission, and an exacerbating force that makes the allergy worse is an increase in tick bites. "One thing that does influence whether you have a shot at remission is whether you stop getting tick bites," Hamner said. "More tick bites can send you back into allergy or keep you there. And so that's one of the really key things, is preventing more tick bites." How to prevent tick bites? According to experts: The prevalence of the allergy has changed the way restaurants are doing business. "Restaurants, food trucks, and other food establishments are including alpha-gal-friendly menu items on their menu," Roden-Reynolds explained. "Alpha-gal is now a selection you can choose on your list of allergies if you're ordering takeout, too."

Why Eli Lilly (LLY) Stock Is Up Today
Why Eli Lilly (LLY) Stock Is Up Today

Yahoo

time2 hours ago

  • Yahoo

Why Eli Lilly (LLY) Stock Is Up Today

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended its positive momentum partly fueled by reports of major insider buying by top executives, including the CEO, which is often seen as a strong vote of confidence. Additionally, news that the company has signed a multi-billion dollar deal with an AI health tech company (Superluminal) to discover and develop new obesity medicines also contributed to the positive sentiment. Finally, the company's decision to increase the price of its popular diabetes and weight-loss drug Mounjaro in the UK, in response to US political pressure, was also seen as a positive for future revenue. After the initial pop the shares cooled down to $705.51, up 3.1% from previous close. Is now the time to buy Eli Lilly? Access our full analysis report here, it's free. What Is The Market Telling Us Eli Lilly's shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 3.1% on the news that reports of significant insider buying by top executives, including the CEO, sent the stock rebounding from a recent selloff. The move came after regulatory filings on Tuesday revealed that several top executives, including CEO David Ricks, had purchased nearly $2.9 million worth of company stock. Ricks alone acquired over $1 million in shares, a move investors often interpret as a strong vote of confidence from leadership. This buying activity follows a significant selloff last week, where the stock dropped about 14% due to disappointing trial data for an oral obesity pill. The insider purchases are seen as a signal that management considers the stock undervalued after the recent decline and believes the market overreacted, providing a catalyst for Wednesday's rebound. Eli Lilly is down 9.3% since the beginning of the year, and at $705.51 per share, it is trading 26.5% below its 52-week high of $960.02 from August 2024. Investors who bought $1,000 worth of Eli Lilly's shares 5 years ago would now be looking at an investment worth $4,656. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

3 ways the GLP-1 market has changed shape this year
3 ways the GLP-1 market has changed shape this year

Yahoo

time3 hours ago

  • Yahoo

3 ways the GLP-1 market has changed shape this year

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo Nordisk are doing all they can to secure their dominance. The two pharma giants recently revealed what they see as the emerging market opportunities, pitfalls and changing dynamics as they continue to compete head to head. Novo's sales rose 18% during the first half compared to the same period last year, but the Danish pharma lowered its revenue and profit outlook for the rest of 2025 due to slower-than-expected growth. Lilly, meanwhile, is taking over the space thanks to the popularity of Zepbound, its tirzepatide drug for obesity. The Indiana-based company reported that revenue rose 38% during the second quarter of the year, and 41% for the first half. Lilly also upped its 2025 guidance due to strong demand for its GLP-1 drugs. The quarterly results highlighted how the two companies are competing against each other as other drugmakers wait on the sidelines for their candidates to move through the clinic. Here's what the latest earnings reports from Lilly and Novo revealed about the evolving GLP-1 market. The market is growing Overall, the GLP-1 market grew in the second quarter, with Lilly's total prescriptions up 41% compared to the same period last year when prescriptions rose just 13%. According to Lilly, the company is taking up even more market share. After eclipsing Novo earlier this year when it secured 53% of the market, Lilly saw its share rise to 57% during the second quarter, according to an investor presentation. The company also said its tirzepatide meds now account for two-thirds of all patients taking obesity drugs. And executives see more upside in the future since only about 4% of Americans were taking a GLP-1 for obesity or diabetes last year. In particular, Lilly is bullish on Zepbound's potential to become the most widely used GLP-1 for obesity. 'While market growth continues to be robust, overall penetration into the addressable population is still low and we believe significantly more patients can benefit from incretin therapy,' Lucas Montarce, Lilly's CFO, said during the earnings call last week. Novo, meanwhile, was singing a different tune in its earnings report, noting that growth of its GLP-1 drugs for diabetes was slowing during the quarter compared to prior years. But with the obesity market expanding, there's still plenty of room to improve according to David Moore, president of Novo Nordisk and executive vice president of U.S. operations. 'The story continues to be about market expansion for obesity,' he said during the quarterly earnings call. The race for the pill is ramping up Both Novo and Lilly are in late-state trials for oral versions of their GLP-1 drugs, and Novo is already pursuing U.S. approval for its once-daily semaglutide pill. The FDA is expected to render a decision regarding the drug later this year. In conjunction with its quarterly earnings report, Lilly announced the latest results from a phase 3 trial of its oral GLP-1, orforglipron, revealing participants lost an average of 12.4% of their weight over 72 weeks. The pill didn't outperform Novo's Wegovy as analysts had hoped, sending Lilly's stock falling in the immediate aftermath of the news despite otherwise stellar earnings results. Still, the company is pushing forward with the pill and working toward regulatory submissions this year, with anticipated results from five trials for diabetes and obesity over the next five months. Lilly also plans to initiate late-stage studies for hypertension and knee osteoarthritis later this year. Even if it's not as effective as Novo's option, Lilly's pill could still appeal to patients. 'Orforglipron has the potential to be a more convenient alternative to injectable treatments and to be utilized to support early disease intervention in the primary care setting,' Lilly's chief scientific officer Dr. Daniel Skovronsky said during the earnings call. Both drugmakers are racing to bring their pill versions to market, and Novo may have an advantage as it looks to regain market share from Lilly. Novo is also looking to differentiate itself through combination therapies, both injectables and pill versions, in the hopes of improving results and reducing side effects. Manufacturing is getting more competitive With their GLP-1 products in high demand, Novo and Lilly have been ramping up manufacturing investments. Amid the threat of tariffs from President Donald Trump, Lilly has poured billions into domestic manufacturing. In February, the pharma giant said it was adding four new manufacturing sites in the U.S. And Novo has been shelling out hundreds of millions to increase manufacturing capacity globally since last year. Novo also closed its $16.5 billion acquisition of contract manufacturer Catalent last year, ensuring its U.S. production footprint would scale to meet demand for GLP-1 drugs. As both drugmakers pour fresh funds into building new facilities, U.S. regions are aiming to attract and retain the pharma giants. Wisconsin Governor Tony Evers offered $100 million in performance-based state tax credits to Eli Lilly last week in connection with the company's $4 billion facility expansion in the state. Lilly CEO David Ricks noted the company 'produced more than 1.6 times the amount of salable incretin doses during the first half of 2025 when compared to the first half of 2024,' thanks to new manufacturing capacity. Lilly also plans to announce two new sites for manufacturing facilities later this year, he said. Recommended Reading With compounders out of the way, Lilly and Novo go after each other Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store